Over the past two decades there has been a great deal of interest in the development of
inhibitors of the cyclin-dependent kinases (CDKs). This attention initially stemmed from …

Background Cancer is a global health challenge, it impacts the quality of life and its
treatment is associated with several side effects. Resistance of the cancer cells to the …

A study on the iridium-catalyzed C–H borylation of heteroarenes is reported. Several
heteroarenes containing multiple heteroatoms were found to be amenable to C–H borylation …

ABSTRACT CDK9 is a protein in constant development in cancer therapy. Herein we
present an overview of the enzyme as a target for cancer therapy. We provide data on its …

Inhibition of cyclin-dependent kinases (CDKs) has become an effective therapeutic strategy
for treating various diseases, especially cancer. Over almost three decades, although great …

Selective inhibition of exclusively transcription‐regulating PTEFb/CDK9 is a promising new
approach in cancer therapy. Starting from lead compound BAY‐958, lead optimization …

Wogonin is a natural product isolated from the Scutellaria baicalensis and has been proved
to be a potent and selective inhibitor of CDK9. Using this scaffold, we designed and …

Simple Summary This review provides an overview of the state of knowledge and general
understanding of CDK inhibitors currently under development or clinically approved, with a …

The sustained cell proliferation resulting from dysregulation of the cell cycle and activation of
cyclin-dependent kinases (CDKs) is a hallmark of cancer. The inhibition of CDKs is a highly …

Morpholine, a six-membered heterocycle containing one nitrogen and one oxygen atom, is a
moiety of great significance. It forms an important intermediate in many industrial and …